Welcome to our dedicated page for Immutep news (Ticker: IMMP), a resource for investors and traders seeking the latest updates and insights on Immutep stock.
Immutep Limited reports clinical and corporate developments as a clinical-stage biotechnology company developing Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune diseases. Its updates center on eftilagimod alfa (efti), a LAG-3 immunotherapy evaluated in cancer studies, and IMP761, a LAG-3 agonist antibody for autoimmune disease.
Recurring company news covers trial results and changes across programs such as TACTI-004, INSIGHT-003 and EFTISARC-NEO, FDA orphan drug designation for efti in soft tissue sarcoma, scientific-conference abstracts, development and commercialization collaborations, quarterly activities reports, cash runway commentary and Nasdaq ADR listing compliance matters.
Immutep Limited (ASX: IMM; NASDAQ: IMMP) announced a cash rebate of A$1,437,826 from the Australian Federal Government’s R&D tax incentive program. This rebate pertains to eligible R&D activities conducted in the fiscal year 2019, particularly related to the TACTI-mel and TACTI-002 clinical trials of its lead compound, eftilagimod alpha. Immutep's approved Advance Finding allows for extended eligibility for tax incentives for its R&D efforts until June 30, 2021. The funding will be directed towards ongoing clinical trials.
Immutep announces a cash payment of €2,173,454 (~US$2,407,817) from the French Government under the Crédit d’Impôt Recherche tax incentive scheme. This program reimburses 30% of eligible R&D expenditures for French companies involved in research. Immutep qualifies through its subsidiary for R&D activities conducted in France. The funds will be allocated to support the global clinical development of eftilagimod alpha and the preclinical development of IMP761.
Immutep Limited (NASDAQ: IMMP) will host a global webcast on June 2, 2020, at 7.30 am AEST / 5.30 pm EDT. The presentation will include an overview of data from the ongoing Phase II TACTI-002 study and interim results from the INSIGHT-004 Phase I trial, as showcased at the 2020 ASCO Virtual Annual Meeting. CEO Marc Voigt and other key executives will lead the session, followed by a Q&A from analysts. Interested participants can register through the company's website.
Summary not available.